logo
#

Latest news with #YevgeniyaKushchaeva

Osteoboost Health Launches FDA-Cleared Prescription Wearable Device for Low Bone Density, Filling Critical Treatment Gap for 60M+ Americans
Osteoboost Health Launches FDA-Cleared Prescription Wearable Device for Low Bone Density, Filling Critical Treatment Gap for 60M+ Americans

Business Wire

time07-05-2025

  • Health
  • Business Wire

Osteoboost Health Launches FDA-Cleared Prescription Wearable Device for Low Bone Density, Filling Critical Treatment Gap for 60M+ Americans

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Osteoboost Health, Inc. today announced the nationwide availability of Osteoboost, the first and only FDA-cleared prescription medical device for low bone density. Osteoboost is a brand-new wearable that bridges the gap between next-generation consumer health technology and rigorously tested medical innovation. Designed for effortless, at-home use, this clinically proven device delivers targeted vibration therapy directly to the spine and hips: areas at high risk for osteoporotic fractures. Osteoboost CEO Laura Yecie s said, 'Osteoboost empowers people to lead longer, stronger, and more active lives. While the belt is sophisticated medical technology rigorously tested and validated for efficacy, the treatment is easy - 30 minutes a day of vibration therapy that can be done while walking, or other activities.' A gold-standard, double-blinded, placebo-controlled clinical trial at the University of Nebraska Medical Center demonstrated that Osteoboost slowed bone density and strength loss in postmenopausal women with osteopenia who used it at least 3 times per week: 85% reduction in the loss of bone density in the spine 83% reduction in the loss of bone strength in the spine 55% reduction in the loss of bone density in the hip 'It's been a long time since we've seen any innovation for bone health, and yet every day I see patients terrified of the risks they face just walking down the street,' said Dr. Yevgeniya Kushchaeva, ​Clinical Director of University of South Florida Health Adult Endocrinology, and Medical Director of Adult Osteoporosis Program. 'Osteoboost did this the right way. They spent years investing in the clinical trial and FDA approval processes - not easy even for larger pharmaceutical companies.' Osteoboost also announced new strategic investments from AARP, Harvard Business School Angels, and She's Independent, plus a follow-on investment from Esplanade Healthtech Ventures. Osteoboost is a medical technology company developing non-invasive, and science-backed solutions for people with low bone density. For more information, including Instructions for Use, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store